Oral Semaglutide
Oral Semaglutide on the Horizon: Novo Nordisk's R&D Prowess Poised to Reshape Treatment Landscape
Novo Nordisk (NYSE: NVO) is on the cusp of revolutionizing the pharmaceutical landscape with compelling advancements in its oral semaglutide pipeline, highlighted by robust positive clinical trial results and imminent regulatory filings. Building on the success of its existing oral semaglutide for type 2 diabetes (Rybelsus), recent Phase 3 studies,